Novo Nordisk says Ozempic shows lower cardiovascular event risk than Eli Lilly's Mounjaro
NVO•Novo Nordisk said a real-world study found adults with type 2 diabetes who increased their Ozempic dose from 1 mg to 2 mg had a lower risk of major cardiovascular events than those who switched to Mounjaro.
1. Study compares treatments
Novo Nordisk said a real-world study found that adults with type 2 diabetes who escalated their Ozempic dose from 1 mg to 2 mg had a lower risk of major cardiovascular events than those who switched to Eli Lilly's Mounjaro.
